New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - glycaemic control victoza is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus.

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; magnesium stearate; isomalt; colloidal anhydrous silica; hypromellose; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; isomalt; magnesium stearate; hypromellose; brilliant blue fcf aluminium lake; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg - tablet, film coated - excipient ingredients: iron oxide yellow; colloidal anhydrous silica; hypromellose; isomalt; titanium dioxide; macrogol 8000; magnesium stearate; brilliant blue fcf aluminium lake; hyprolose - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arginine hydrochloride, quantity: 600 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 jan 1991 : arginine stimulates the release of growth hormone by the pituitary gland and may be used instead of , or in addition to, other tests such as insulin-induced hypoglycaemia, for the evaluation of growth disorders; false positive and false negative results are relatively common and evaluation therefore should not be made on the basis of a single arginine test. arginine is used as an acidifying agent in severe metabolic alkalosis. arginine is used in some conditions accompanied by hyperammonaemia stemming from inborn errors of the urea cycle, particularly where there is a severe deficiency of ornithine carbamoyl transferase or carbamoyl phosphate synthetase where respiratory alkalosis is present.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril arginine -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril arginine -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril arginine -

New Zealand - English - Medsafe (Medicines Safety Authority)

intermed medical ltd - arginine 6 mg/ml; histidine 4.29 mg/ml; isoleucine 4.62 mg/ml; leucine 7.26 mg/ml; lysine 5.35 mg/ml; methionine 7.26 mg/ml; phenylalanine 7.26 mg/ml; threonine 3.3 mg/ml; tryptophan 1.65 mg/ml; valine 5.28 mg/ml - solution for infusion - 5.2 % - active: arginine 6 mg/ml histidine 4.29 mg/ml isoleucine 4.62 mg/ml leucine 7.26 mg/ml lysine 5.35 mg/ml methionine 7.26 mg/ml phenylalanine 7.26 mg/ml threonine 3.3 mg/ml tryptophan 1.65 mg/ml valine 5.28 mg/ml excipient: acetic acid hydrochloric acid nitrogen sodium metabisulfite water for injection